As scruti­ny in­to drug prices in­ten­si­fies, Lil­ly launch­es half price Hu­ma­log; BioX­cel, Nek­tar ex­pand col­lab to in­clude Baven­cio in com­bo pan­cre­at­ic can­cer ther­a­py

→ Bi­par­ti­san furor against drug prices in the Unit­ed States is hav­ing a grow­ing im­pact on phar­ma­ceu­ti­cal com­pa­ny de­ci­sions. Fol­low­ing Am­gen $AMGN and part­ners Re­gen­eron $REGN and Sanofi $SNY move to slash the price of their re­spec­tive PC­SK9 cho­les­terol drugs by 60%, Lil­ly $LLY on Mon­day made its own pledge: to of­fer a half-price gener­ic of its pop­u­lar in­sulin Hu­ma­log (which gen­er­at­ed near­ly $3 bil­lion in 2018 sales), at a time when anec­do­tal re­ports of US di­a­bet­ics ra­tioning and in cer­tain cas­es fore­go­ing in­sulin are do­ing the rounds.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.